Dr. Kelli A. Reardon, MD

Dr. Reardon practices at Novant Health Forsyth Medical Center in Winston Salem, North Carolina, part of Novant Health.

Dr. Reardon's NPI, 1013175769, was assigned on May 29, 2008. Dr. Reardon graduated from University of Virginia School of Medicine in 2008. Dr. Reardon holds North Carolina license 2015-01879.

Dr. Reardon's primary practice is Novant Health Forsyth Medical Center, at 3333 Silas Creek Parkway, Winston Salem, NC 27103 in Forsyth County. The practice phone is (336) 718-5000.

Dr. Reardon's primary practice is Novant Health Forsyth Medical Center in Winston Salem, North Carolina, part of Novant Health. Dr. Reardon is also affiliated with Novant Health Thomasville Medical Center. The medical group on file is Piedmont Radiation Oncology - Forsyth. Dmand AI also links Dr. Reardon to 1 more hospital outpatient department, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reardon practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Reardon's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Reardon is licensed in North Carolina.

CMS data shows 1,214 Medicare services from Dr. Reardon across 15 procedure codes in 2024, for 225 Medicare patients. Medicare paid $92,956 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 225 Medicare patients who saw Dr. Reardon in 2024. The largest group is 65 to 74, with 112 patients. 75% of them have cancer, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Reardon's median patient age at 72, with 59% women.

In 2024, Dr. Reardon wrote 45 Medicare Part D claims for 24 patients. 96% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $1,996 in total drug cost. In 2023, CMS named 31 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Reardon for performance year 2024, reported as part of a group. Dr. Reardon accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Reardon, published from 2010 to 2018. 2015 was the busiest year, with 4. The most frequent topics are Breast Neoplasms. Dr. Reardon's most frequent co-authors are Daniel Trifiletti, MD, David R. Brenin, MD and Anneke T. Schroen, MD.

CMS Open Payments shows 19 general payments to Dr. Reardon from 12 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 100% of the total. Abbott Laboratories paid the most, $97.

Dr. Reardon graduated from University of Virginia School of Medicine in 2008.